Daratumumab combination treatment approved for NHS use in England and Wales through the Cancer Drugs Fund
This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…